January 26, 2018 3:40pm
VSTM is up +$0.16 or +5.06% to $3.39 in a day’s range of $3.23 to $3.49
VSTM announced that a poster highlighting the synergistic effects of duvelisib in combination with immune checkpoint or co-stimulatory antibodies in preclinical models of B cell lymphoma.
... at ASCO-SITC Clinical Immuno-Oncology Symposium being held January 25-27, 2018 in San Francisco.
Duvelisib is an oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma that is currently being developed for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL). In addition, duvelisib is being studied in other hematologic malignancies including peripheral T cell lymphoma (PTCL).
“In patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and follicular lymphoma, oral duvelisib monotherapy has demonstrated efficacy, along with a consistent and manageable safety profile. However, emerging data suggest that some aggressive lymphomas will likely require combination therapy to improve clinical outcomes,” said Jonathan Pachter, PhD, Chief Scientific Officer of Verastem.
Oral duvelisib is the first PI3K inhibitor to show efficacy as an oral monotherapy in a randomized P3 study in patients with relapsed or refractory CLL/SLL (the DUO™ study).
- In the P2 DYNAMO study, duvelisib achieved meaningful clinical activity in patients diagnosed with follicular lymphoma (FL), small lymphocytic lymphoma (SLL), or marginal zone lymphoma (MZL) whose disease is refractory to rituximab and to a chemotherapy regimen or radioimmunotherapy.
- Verastem plans to submit a New Drug Application (NDA) to the FDA during Q1/18 requesting full approval of duvelisib for the treatment of patients with relapsed or refractory CLL/SLL and accelerated approval for the treatment of patients with relapsed or refractory follicular lymphoma (FL).